Skip to main content
    Q

    Qiagen NV (QGEN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $49.80
    -0.09 (-0.18%)

    Market Cap: $10.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Qiagen NV (QGEN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Qiagen NV (QGEN) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Qiagen NV reported EPS of $0.65, above the $0.63 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +5.80%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.67
    Range$0.63 - $0.70
    11 analysts
    Revenue Consensus
    $584.80M
    Range$557.19M - $613.20M
    11 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.56
    Range$0.54 - $0.58
    6 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.58-3.6%
    60d ago$0.56+0.2%
    30d ago$0.56+0.2%
    7d ago$0.560.0%
    Current$0.56
    Revenue Consensus
    $511.64M
    Range$505.31M - $520.00M
    4 analysts

    Next Report

    QGEN has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.1% above the $0.62 reported for the quarter ended Dec 31, 2025.

    QGEN Earnings Call

    The latest QGEN earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, QGEN beat 32, missed 2 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $547.87M, up 2.9% from $532.58M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.65$0.63$0.61 - $0.65+3.17%Beat+1.6%91 up, 0 downNov 4, 2026$547.87M
    Jun 30, 2026$0.62$0.60$0.59 - $0.61+3.33%Beat-1.6%101 up, 0 downAug 5, 2026$535.04M
    Mar 31, 2026$0.54$0.54$0.54 - $0.540.00%In line-6.9%30 up, 0 downMay 6, 2026$492.32M
    Dec 31, 2025$0.62$0.62$0.59 - $0.640.00%In line-3.1%100 up, 3 downFeb 4, 2026$540.42M
    Sep 30, 2025$0.64$0.62N/A+3.23%Beat+3.2%110 up, 2 downNov 4, 2025$532.58M
    Jun 30, 2025$0.63$0.63N/A0.00%In line+5.0%1110 up, 0 downAug 5, 2025$533.54M
    Mar 31, 2025$0.58$0.54$0.48 - $0.60+7.41%Beat+16.0%122 up, 0 downMay 7, 2025$483.46M
    Dec 31, 2024$0.64$0.65N/A-1.54%Miss+6.7%111 up, 2 downFeb 5, 2025$521.20M
    Sep 30, 2024$0.62$0.59N/A+5.08%Beat+10.7%121 up, 0 downNov 6, 2024$501.87M
    Jun 30, 2024$0.60$0.56N/A+7.14%Beat+5.3%140 up, 0 downJul 31, 2024$496.35M
    Mar 31, 2024$0.50$0.47N/A+6.38%Beat-12.3%140 up, 0 downApr 29, 2024$458.80M
    Dec 31, 2023$0.60$0.60N/A0.00%In line+1.7%12N/AFeb 6, 2024$509.16M
    Sep 30, 2023$0.56$0.54N/A+3.70%Beat-5.1%110 up, 1 downOct 30, 2023$475.89M
    Jun 30, 2023$0.57$0.56N/A+1.79%Beat0.0%111 up, 0 downAug 8, 2023$494.86M
    Mar 31, 2023$0.57$0.51N/A+11.76%Beat-36.0%110 up, 0 downMay 3, 2023$485.40M
    Dec 31, 2022$0.59$0.52N/A+13.46%Beat-28.9%111 up, 0 downFeb 7, 2023$497.98M
    Sep 30, 2022$0.59$0.51N/A+15.69%Beat-9.2%61 up, 0 downNov 7, 2022$499.63M
    Jun 30, 2022$0.57$0.51N/A+11.76%Beat-24.0%N/A0 up, 0 downJul 26, 2022$515.51M
    Mar 31, 2022$0.89$0.80N/A+11.25%Beat+20.3%52 up, 0 downApr 26, 2022$628.39M
    Dec 31, 2021$0.83$0.68N/A+22.06%Beat+9.2%5N/AFeb 8, 2022$582.40M
    Sep 30, 2021$0.65$0.60N/A+8.33%Beat0.0%6N/ANov 3, 2021$534.75M
    Jun 30, 2021$0.75$0.74N/A+1.35%Beat+23.0%13N/AJul 29, 2021$567.31M
    Mar 31, 2021$0.74$0.70N/A+5.71%Beat+94.7%11N/AMay 3, 2021$567.21M
    Dec 31, 2020$0.76$0.71N/A+7.04%Beat+40.7%14N/AFeb 9, 2021$571.23M
    Sep 30, 2020$0.65$0.62N/A+4.84%Beat+62.5%12N/AOct 27, 2020$483.76M
    Jun 30, 2020$0.61$0.54$0.35 - $0.55+12.96%Beat+64.9%10N/AAug 4, 2020$443.25M
    Mar 31, 2020$0.38$0.30$0.18 - $0.31+26.67%Beat+26.7%10N/AMay 6, 2020$372.10M
    Dec 31, 2019$0.54$0.49N/A+10.20%Beat+20.0%14N/AFeb 4, 2020$413.47M
    Sep 30, 2019$0.40$0.39N/A+2.56%Beat+2.6%12N/AOct 30, 2019$382.69M
    Jun 30, 2019$0.37$0.37N/A0.00%In line0.0%12N/AJul 24, 2019$381.61M
    Mar 31, 2019$0.30$0.29N/A+3.45%Beat+3.4%10N/AMay 6, 2019$348.65M
    Dec 31, 2018$0.45$0.44N/A+2.27%Beat-6.2%12N/AFeb 4, 2019$403.17M
    Sep 30, 2018$0.39$0.37N/A+5.41%Beat+8.3%11N/AOct 29, 2018$377.91M
    Jun 30, 2018$0.37$0.36N/A+2.78%Beat+12.1%11N/AJul 31, 2018$377.20M
    Mar 31, 2018$0.29$0.27N/A+7.41%Beat+31.8%11N/AMay 2, 2018$343.57M
    Dec 31, 2017$0.48$0.46N/A+4.35%Beat+9.1%11N/AJan 31, 2018$396.86M
    Sep 30, 2017$0.36$0.36N/A0.00%In line+5.9%11N/ANov 6, 2017$363.98M
    Jun 30, 2017$0.33$0.32N/A+3.13%Beat+17.9%13N/AJul 27, 2017$348.99M
    Mar 31, 2017$0.22$0.23N/A-4.35%Miss0.0%N/AN/AMay 2, 2017$307.71M
    Dec 31, 2016$0.44$0.43N/A+2.33%Beat+22.2%N/AN/AFeb 1, 2017$366.51M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.47, up 4.7% from the year before. It was $1.28 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.47+4.7%
    Dec 31, 2024$2.36+2.6%
    Dec 31, 2023$2.30-12.9%
    Dec 31, 2022$2.64-11.1%
    Dec 31, 2021$2.97+23.8%
    Dec 31, 2020$2.40+49.1%
    Dec 31, 2019$1.61+7.3%
    Dec 31, 2018$1.50+7.9%
    Dec 31, 2017$1.39+8.6%
    Dec 31, 2016$1.28N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 7,400 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20267,43412
    2025Q4Dec 31, 20257,74813
    2025Q3Sep 30, 20257,58712
    2025Q2Jun 30, 20257,83816
    2025Q1Mar 31, 20256,69112
    2024Q4Dec 31, 20249,23313
    2024Q3Sep 30, 20248,51312
    2024Q2Jun 30, 20247,91816

    2026Q2 Earnings Call

    Opening remarks

    Daniel Wendorff Vice President, Head of Investor Relations Thank you, operator, and welcome to our call for the second quarter of 2026. We appreciate your time and interest in Qiagen. Joining the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team. As always, today's call is being webcast live and will be archived in the Investor Relations section of our website at www.qiagen.com, where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements. Actual results may differ materially from those projected due to a number of factors outlined in our most recent Form 20-F and other filings with the U.S. Securities and Exchange Commission. We will also refer to certain financial measures not prepared in accordance with U.S. generally accepted accounting principles or GAAP that provide additional insights into our performance. Reconciliations to the most directly comparable GAAP figures are in the release and presentation. All references to earnings per share refer to adjusted diluted EPS. With that, let me hand over the call to you, Thierry.

    Thierry Bernard Chief Executive Officer Thank you, Daniel. Hello, and good morning, good afternoon or good evening, depending on where you are in the world, and thank you for joining us. Let me start by thanking again our teams across Qiagen for their continued dedication and disciplined execution. Their focus enabled us to deliver results above our outlook while continuing to invest in our portfolio and focus on profitable growth. Let me now walk you through our key messages for today. First, we exceeded our outlook for both sales and adjusted EPS. Net sales were $535 million and unchanged on both a reported basis and at CER. This was ahead of our outlook for an approximately 2% decline CER. Adjusted diluted EPS was $0.62 on both a reported basis and at CER again, above our outlook of at least $0.60 at CER. Those results demonstrate the resilience of our business and provide further confidence in our outlook for the year. Second key message, our growth pillars delivered 5% growth at CER, profitably above market growth. Sample Technologies led the quarter, reflecting continued demand for our sample preparation solutions. QIAcuity delivered another solid quarter, driven by healthy consumables demand. QDI, our bioinformatics business, also performed well, led by our clinical application. QuantiFERON returned to growth as solid demand across many testing groups more than offset the significant decline in U.S. immigration testing demand. This U.S. immigration testing demand decrease is what we highlighted at the end of our Q1 2026.

    Frequently Asked Questions About QGEN

    When is Qiagen NV's next earnings date?

    Qiagen NV's next earnings report is expected for Feb 2, 2027.

    Did QGEN beat earnings estimates last quarter?

    Yes. Qiagen NV reported EPS of $0.65 for the quarter ended Sep 30, 2026, above the $0.63 estimate, a 3.17% surprise.

    What EPS do analysts expect from QGEN next quarter?

    The consensus EPS estimate for Qiagen NV for the quarter ending Dec 31, 2026 is $0.67 from 11 analysts, with estimates from $0.63 to $0.70.

    How often does QGEN beat earnings estimates?

    Qiagen NV beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +1.95%.